- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12 Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy
This study is looking at new eye drops for people with an eye condition called Fuchs Endothelial Corneal Dystrophy. It checks if the drops help people see better after cataract surgery and another eye procedure. The study lasts about a year.
For: Fuchs Endothelial Corneal DystrophyGermany · Denmark · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy
This study looks at a new eye drop, Ripasudil, for people with Fuchs Endothelial Corneal Dystrophy after a special eye operation called descemetorhexis. We want to see if the drops help vision improve safely and quickly.
For: Fuchs Endothelial Corneal DystrophyDenmark · Spain · Germany